{"abstract": "When Carl C. Icahn purchased 1-percent stakes in two well-established biotech companies, MedImmune and Biogen Idec, the moves drew little attention. ", "web_url": "https://dealbook.nytimes.com/2007/11/15/genzyme-may-be-icahns-next-biotech-target/", "snippet": "", "lead_paragraph": "When Carl C. Icahn purchased 1-percent stakes in two well-established biotech companies, MedImmune and Biogen Idec, the moves drew little attention. ", "source": "The New York Times", "multimedia": [], "headline": {"main": "Genzyme May Be Icahn\u2019s Next Biotech Target", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2007-11-15T22:22:24+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Dealbook", "person": [{"firstname": "Dealbook", "middlename": null, "lastname": "", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/95b4e851-9335-500d-9ff9-6907f6eb19f1", "word_count": 364, "uri": "nyt://article/95b4e851-9335-500d-9ff9-6907f6eb19f1"}